New hope for Hard-to-Treat lymphoma: experimental drug DZD8586 enters phase 2 trial

NCT ID NCT06539195

Completed Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This phase 2 trial tests an experimental drug called DZD8586 in 59 adults with diffuse large B-cell lymphoma that has come back or not responded to previous treatment. The study aims to see if the drug can shrink tumors and to understand its side effects and how the body processes it. Participants take one of three daily doses of DZD8586.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DZD8586
What this could lead to: If successful, this could provide a new oral treatment option for patients with DLBCL that has returned or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial with no control group, so results may not confirm effectiveness. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, 300020, China
Research Site

Hefei, Anhui, 230031, China
Research Site

Beijing, Beijing Municipality, 100083, China
Research Site

Guangzhou, Guangdong, 510060, China
Research Site

Nanning, Guangxi, 530016, China
Research Site

Zhengzhou, Henan, 450003, China
Research Site

Wuhan, Hubei, 430023, China
Research Site

Changsha, Hunan, 410031, China
Research Site

Jinan, Shandong, 250117, China
Research Site

Linyi, Shandong, 276002, China
Research Site

Xi’an, Shanxi, 710061, China
Research Site

Chengdu, Sichuan, 610041, China
Research Site

Tianjin, Tianjin Municipality, 300181, China
Research Site

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.